A new license to adapt EORTC questionnaires into electronic versions
15 Apr 2021
As of 15 May 2021, the EORTC will introduce a new license for any Electronic Outcome Assessment (eCOA) provider or other entity (e.g. CRO or pharmaceutical company) adapting – or “migrating” – the EORTC Quality of Life Group questionnaires and modules into electronic versions (e-versions) and making these e-versions available for use in clinical trials or other studies. This license is subject to a royalty fee when the e-version(s) will be used in commercial trials or studies. When adapting the questionnaires into an in e-version for use in academic trials, the license will still be required, however no royalty fee will be charged.
There are two types of licenses:
- The “Study Solution” where a provider will adapt an EORTC questionnaire for a single study; or
- The “Library Solution” where a provider will create a “library” of e-versions of EORTC Quality of Life Group Questionnaire, available for use in clinical trials and studies.
For any further queries regarding these licensing solutions, their scope and fees, please contact EORTC at: qol.contracts@eortc.org
With this new license, the EORTC aims to improve the quality and consistency of the e-versions of its questionnaires.
We thank you for your understanding of this evolution of EORTC processes and we look forward to a continued collaboration.
Related News
Professor Benjamin Besse becomes President of EORTC
26 Jun 2026
CCTG, EORTC and UK3CR welcome G7 commitment to accelerate global progress against cancer
24 Jun 2026
EORTC welcomes EU Biotech Act and calls for refinements to enable patient-centred trials
24 Jun 2026
New study confirms a key quality of life tool can be used with adolescents with cancer
9 Jun 2026
“Changing practice, improving lives”: EORTC publishes its Annual Report 2025
8 Jun 2026
This Clinical Trials Day, EORTC announces the upcoming Summit for Clinical Cancer Research
20 May 2026
Long-term EORTC trial challenges assumptions about lymph node radiation therapy in breast cancer
17 May 2026
Multinational study provides new evidence for the value of response-adapted, personalised treatment in Hodgkin lymphoma
1 May 2026
EORTC’s presence at ESTRO 2026
30 Apr 2026
Independent, academic cancer trials are vital to improve patient outcomes worldwide
28 Apr 2026
